Investec buys into crowd-funding venture
Investec Australia is aiming to harness the distribution power and capital intermediation capabilities of crowd-funding through its investment in Equitise.
The funds management firm announced it had taken a 20 per cent stake in the Trans-Tasman business.
Investec Australia head of direct investments, David Philips, said the firm had a "strong history of asset and funds management and understands the power of distribution and capital intermediation".
"We see Equitise as an important part of the changes we consider are coming in this space, which will bring cost, time and administrative efficiencies to the process of bringing together providers and users of risk capital," he said.
Investec Australian chief executive, Milton Samios, said Equitise had developed its business model in New Zealand, where legislation has been enacted to removed limits or caps on crowd-funding investment, enabling investors to control how much money they put into projects.
"We are excited about the ability to participate in the growth of equity crowd-funding in Australia and New Zealand via our significant stake in Equitise," he said.
"We are particularly attracted to the business model Equitise continues to develop, including the creation of a ‘syndicate' investment platform that will allow groups of like-minded investors to create their own investor club for new investment opportunities — essentially taking the ‘angel investor' model on-line."
Investec's 20 per cent stake in Equisite makes it the largest stakeholders, behind the company's founders, with H2 Ventures and Tank Stream Ventures also holding equity in the business.
AUTHOR
Nicholas O'Donoghue
Recommended for you
Global X has painted a worrying picture for active ETFs in Australia, with investor adoption proving uneven and the popularity of its low-cost index counterparts only growing stronger.
Australian equity ETFs attracted record inflows of $3.2 billion in 1Q25, while heightened volatility led to a decline in flows for global equity ETFs, according to Vanguard.
The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under management, quarterly flows show.
GQG Partners has revealed its quarterly flows for the first three months of 2025 were up 5.8 per cent, after a difficult final quarter of 2024 as a result of institutional redemptions.
